90 related articles for article (PubMed ID: 7514714)
1. Effects of tyrphostins on the activated c-src protein in NIH/3T3 cells.
Agbotounou WK; Levitzki A; Jacquemin-Sablon A; Pierre J
Mol Pharmacol; 1994 May; 45(5):922-31. PubMed ID: 7514714
[TBL] [Abstract][Full Text] [Related]
2. Selective platelet-derived growth factor receptor kinase blockers reverse sis-transformation.
Kovalenko M; Gazit A; Böhmer A; Rorsman C; Rönnstrand L; Heldin CH; Waltenberger J; Böhmer FD; Levitzki A
Cancer Res; 1994 Dec; 54(23):6106-14. PubMed ID: 7954456
[TBL] [Abstract][Full Text] [Related]
3. Alterations of the cytoskeletal organization in tumor cell lines by a cardiotonic drug, vesnarinone, through protein tyrosine phosphorylation.
Yoshinaka Y; Katoh I; Kyushiki H; Sakamoto Y
Exp Cell Res; 1995 Jul; 219(1):21-8. PubMed ID: 7543053
[TBL] [Abstract][Full Text] [Related]
4. The degree of inhibition of protein tyrosine kinase activity by tyrphostin 23 and 25 is related to their instability.
Ramdas L; McMurray JS; Budde RJ
Cancer Res; 1994 Feb; 54(4):867-9. PubMed ID: 7508821
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of phospholipase D of human platelets by protein tyrosine kinase inhibitors.
Martinson EA; Scheible S; Presek P
Cell Mol Biol (Noisy-le-grand); 1994 Jul; 40(5):627-34. PubMed ID: 7526916
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of platelet-derived growth factor and epidermal growth factor receptor signaling events after treatment of cells with specific synthetic inhibitors of tyrosine kinase phosphorylation.
Lipson KE; Pang L; Huber LJ; Chen H; Tsai JM; Hirth P; Gazit A; Levitzki A; McMahon G
J Pharmacol Exp Ther; 1998 May; 285(2):844-52. PubMed ID: 9580635
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of topoisomerase I activity by tyrphostin derivatives, protein tyrosine kinase blockers: mechanism of action.
Aflalo E; Iftach S; Segal S; Gazit A; Priel E
Cancer Res; 1994 Oct; 54(19):5138-42. PubMed ID: 7923131
[TBL] [Abstract][Full Text] [Related]
8. Mutational activation of pp60(c-src) leads to a tumorigenic phenotype in a preneoplastic Syrian hamster embryo cell line.
Lansing TJ; Turk BF; Kanner SB; Gilmer TM
Cancer Res; 1997 May; 57(10):1962-9. PubMed ID: 9157992
[TBL] [Abstract][Full Text] [Related]
9. Tyrphostin induced growth inhibition: correlation with effect on p210bcr-abl autokinase activity in K562 chronic myelogenous leukemia.
Kaur G; Gazit A; Levitzki A; Stowe E; Cooney DA; Sausville EA
Anticancer Drugs; 1994 Apr; 5(2):213-22. PubMed ID: 8049505
[TBL] [Abstract][Full Text] [Related]
10. Increased levels of p21ras-GTP and enhanced DNA synthesis accompany elevated tyrosyl phosphorylation of GAP-associated proteins, p190 and p62, in c-src overexpressors.
Chang JH; Wilson LK; Moyers JS; Zhang K; Parsons SJ
Oncogene; 1993 Apr; 8(4):959-67. PubMed ID: 7681161
[TBL] [Abstract][Full Text] [Related]
11. Plasminogen activator inhibitor type-1 gene expression and induced migration in TGF-beta1-stimulated smooth muscle cells is pp60(c-src)/MEK-dependent.
Samarakoon R; Higgins CE; Higgins SP; Kutz SM; Higgins PJ
J Cell Physiol; 2005 Jul; 204(1):236-46. PubMed ID: 15622520
[TBL] [Abstract][Full Text] [Related]
12. SKI-606 decreases growth and motility of colorectal cancer cells by preventing pp60(c-Src)-dependent tyrosine phosphorylation of beta-catenin and its nuclear signaling.
Coluccia AM; Benati D; Dekhil H; De Filippo A; Lan C; Gambacorti-Passerini C
Cancer Res; 2006 Feb; 66(4):2279-86. PubMed ID: 16489032
[TBL] [Abstract][Full Text] [Related]
13. Phosphorylation of growth factor receptor binding protein-2 by pp60c-src tyrosine kinase.
Jones DA; Benjamin CW
Arch Biochem Biophys; 1997 Jan; 337(2):143-8. PubMed ID: 9016807
[TBL] [Abstract][Full Text] [Related]
14. Alterations in EGF-dependent proliferative and phosphorylation events in squamous cell carcinoma cell lines by a tyrosine kinase inhibitor.
Brunton VG; Carlin S; Workman P
Anticancer Drug Des; 1994 Aug; 9(4):311-29. PubMed ID: 7916899
[TBL] [Abstract][Full Text] [Related]
15. Src is required for cell migration and shape changes induced by fibroblast growth factor 1.
Liu J; Huang C; Zhan X
Oncogene; 1999 Nov; 18(48):6700-6. PubMed ID: 10597276
[TBL] [Abstract][Full Text] [Related]
16. Regulation of the cellular src protein tyrosine kinase: interactions of the carboxyl terminal sequences residing between the kinase domain and tyrosine-527.
Cobb BS; Parsons JT
Oncogene; 1993 Nov; 8(11):2897-903. PubMed ID: 7692368
[TBL] [Abstract][Full Text] [Related]
17. Tyrosine kinase inhibitors. 6. Structure-activity relationships among N- and 3-substituted 2,2'-diselenobis(1H-indoles) for inhibition of protein tyrosine kinases and comparative in vitro and in vivo studies against selected sulfur congeners.
Showalter HD; Sercel AD; Leja BM; Wolfangel CD; Ambroso LA; Elliott WL; Fry DW; Kraker AJ; Howard CT; Lu GH; Moore CW; Nelson JM; Roberts BJ; Vincent PW; Denny WA; Thompson AM
J Med Chem; 1997 Feb; 40(4):413-26. PubMed ID: 9046331
[TBL] [Abstract][Full Text] [Related]
18. Puromycin is a potent and specific inhibitor of tyrosine kinase activity in HL-60 cells.
Davidoff AN; Mendelow BV
Anticancer Res; 1992; 12(5):1761-6. PubMed ID: 1280034
[TBL] [Abstract][Full Text] [Related]
19. The tyrosine kinase inhibitor tyrphostin blocks the cellular actions of nerve growth factor.
Ohmichi M; Pang L; Ribon V; Gazit A; Levitzki A; Saltiel AR
Biochemistry; 1993 May; 32(17):4650-8. PubMed ID: 7683492
[TBL] [Abstract][Full Text] [Related]
20. Activation of the mitogen-activated protein kinase cascade by tyrphostin (RG 50864).
Agbotounou WK; Mousset S; Piperno S; Pierre M; Jacquemin-Sablon A; Pierre J
Biochem Pharmacol; 1994 Aug; 48(3):505-15. PubMed ID: 8068037
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
